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RESEARCH ARTICLE

Open Access

Biochemical comparison of osteoarthritic knees
with and without effusion
Nicole M Cattano1†, Jeffrey B Driban2†, Easwaran Balasubramanian3†, Mary F Barbe4†, Mamta Amin4† and
Michael R Sitler5*†

Abstract
Background: Several symptom-relieving interventions have been shown to be efficacious among osteoarthritis
(OA) patients with knee effusion; however, not every symptomatic knee OA patient has clinical effusion. Results
may be over-generalized since it is unclear if effused knees represent a unique pathological condition or subset
compared to knees without effusion. The primary purpose of this study was to determine if biochemical
differences existed between OA knees with and without effusion.
Methods: The present cross-sectional study consisted of 22 volunteers (11 with knee effusion, 11 without knee
effusion) with confirmed late-stage radiographic knee OA (Kellgren-Lawrence score ≥ 3). Synovial fluid samples
were collected and analyzed using a custom multiplex enzyme-linked immunosorbent assay to determine eight
specific biomarker concentrations (e.g., catabolic, anabolic).
Results: Matrix metalloproteinase (MMP)-3, tissue inhibitor of MMPs (TIMP)-1, TIMP-2, and interleukin-10 were
significantly higher in the knees with effusion than in the knees without effusion.
Conclusions: The biochemical differences that existed between knees with and without effusion provide support
that OA subsets may exist, characterized by distinct biochemical characteristics and clinical findings (e.g., effusion).

Background
Osteoarthritis (OA) is a heterogeneous disease disabling
more than 27 million United States adults [1]. Patients
with knee OA commonly present with pain, stiffness, effusion, and functional impairment. Symptoms may be modulated by effusion as patients with knee effusion are often
more symptomatic [2-4] and have greater improvement in
pain and function to symptom-modifying interventions
than patients without knee effusion [5]. Based on magnetic
resonance imaging findings, patients with knee effusion
comprise 30 to 76% of patients with knee OA [6,7]. OA
knees with effusion, particularly those with active effusion
processes, may be a discreet subset of patients with unique
clinical characteristics (e.g., effusion, increased symptoms,
increased therapeutic response) and at greater risk for cartilage loss over time [8,9]. Although knees with effusion
respond well to pain-relieving treatments, there is potential

for over generalization of results since it is unclear if OA
knees with and without effusion represent unique biochemical conditions. Biochemical analyses may distinguish
unique OA phenotypes [10] which may be clinically distinct (e.g., different symptom severity) and respond
uniquely to interventions.
The primary purpose of this study was to determine if
biochemical differences existed between OA knees with
and without clinical effusion. The hypothesis of this study
was that OA knees with effusion would have elevated
inflammatory mediators when compared to OA knees
without effusion. Highly sensitive clinical and biochemical
data may help identify discreet subsets of patients that can
be targeted for improved diagnosis, interventions, and genotyping of OA, [5,11] ultimately, improving the overall
care of knee OA patients.

Methods
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Study Design and Participants

This cross-sectional study was approved by the Institutional Review Board, and informed consent was obtained
from each patient prior to participation in the study.

© 2011 Cattano et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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Participants were a sample of convenience and recruited
from November 2009 to August 2010 at an orthopedic
practice with a board-certified orthopedic surgeon specializing in hip and knee arthroplasty. Twenty-two
volunteers (11 knees with effusion, 11 knees without
effusion) with late-stage knee OA (Kellgren-Lawrence
score ≥ 3) [12] participated in the study. Prior standard
weight-bearing anterior-posterior radiographs with
knees in full extension were used to assess OA severity
utilizing the Kellgren-Lawrence score [13]. New radiographs were ordered and graded by the orthopedic surgeon if the participant’s radiographs were taken more
than 12 months prior to study inclusion. An investigator-generated medical history form was used to screen
for exclusion criteria, as well as to record medication
and supplement use, injury history, effusion history, and
sport participation history. Patients were excluded from
the study if they indicted acute knee trauma (i.e., injury,
surgery) within three months of study participation,
intraarticular corticosteroid knee injection within thirty
days prior to study participation, or documented history
of other forms of arthritis (e.g., rheumatoid, gout,
pseudogout).
Effusion Status

Effusion status was based on a clinical examination by the
orthopedic surgeon, utilizing observation, palpation, a
modified patellar ballottement test [14], and whether or
not aspiration of the knee was successful. Knee with effusion was defined as a knee that felt and looked swollen,
had a positive patellar ballottement test, and did not
require saline injection for synovial fluid aspiration. A
knee without effusion was defined as a knee that did not
feel or look swollen, had a negative patellar ballottement
test, and required a saline injection to successfully aspirate
synovial fluid.
Sample Acquisition, Storage, and Analysis

Upon completion of all study-related documentation and
assessment, the participant’s involved OA knee joint was
aspirated in accordance with the orthopaedic surgeon’s
standard procedures. The aspiration consisted of vigorously cleaning the needle insertion site with isopropyl
alcohol and using an 18 to 21 gauge 3.81 cm disposable
needle with a 20 or 60 cm3 syringe to aspirate the joint
through the lateral suprapatellar pouch. If the knee did
not have an effusion, the physician injected 5 to 15 cm3
of sterile saline into the knee to “washout” the synovial
fluid prior to aspiration. A successful saline-assisted
aspiration was defined by the recovery of fluid with the
color of healthy synovial fluid. For all knees, the physician
aspirated as much synovial fluid as could be drawn,
which was then visually inspected to ensure that it was a
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healthy color. Healthy synovial fluid was successfully
obtained from all 22 volunteers, and no samples were
excluded based on signs of blood, turbidity, or sepsis.
Synovial Fluid Analysis

A portion (1.0 to 2.0 cc) of the aspirated synovial fluid
was placed in a cryovial and stored in a -80°C freezer
until all of the samples were collected. Once all synovial
fluid samples were collected, they were shipped to
Aushon Biosystems Laboratory (Billerica, MA) without
centrifuging for analysis. Knee synovial fluid biomarker
concentrations were analyzed with a custom human
SearchLight Proteome Multiplex Protein Array. The custom array is a quantitative multiplexed sandwich
enzyme-linked immunosorbent assay, containing eight
different antibodies. The study focused on eight specific
biomarkers, which were categorized as follows: (1) protective or anabolic-associated biomarkers (i.e., interleukin
[IL]-10, IL-13, tissue inhibitor of matrix metalloproteinase [TIMP]-1, TIMP-2, and osteoprotegerin [OPG]), (2)
anabolic biomarker associated with cartilage ossification
and neovascularization (i.e., vascular endothelial growth
factor [VEGF]), (3) catabolic-associated biomarker (i.e.,
matrix metalloproteinase [MMP]-3), and (4) pro-inflammatory associated biomarker (i.e., IL-1b). All of these
biomarkers have been reported to be altered in the synovial fluid of OA joints in comparison to healthy, non-OA
knees [10,15]; however, no distinction was made between
OA knees with and without effusion in these previous
studies.
Concentrations of each biomarker were analyzed in
duplicate and then averaged. In order to take into account
the injection of saline into the non-effused knees, cytokine
data were normalized to the total protein content of each
sample, which was determined by a bicinchoninic acid
assay (ThermoScientific, Chicago, IL). Normalization of
the data allowed for comparison between the two groups,
as knees without effusion required saline-assisted aspirations that diluted an unknown amount of synovial fluid,
which was not the case for the knees with effusion.
Validity of the SearchLight proteome assays has been
established through the spiked recovery rates for the 8
biomarkers analyzed, which ranged from 62 to 134%
(mean recovery ranges from 76 to 114%). Sensitivity and
intra-assay coefficient of variation measures for the eight
biomarkers analyzed were: IL- 10 (sensitivity = 0.8 pg/
mL, intra-assay coefficient of variation = 6.7%), IL-13
(sensitivity = 0.4 pg/mL, intra-assay coefficient of variation = 8.1%), TIMP-1 (sensitivity = 9.8 pg/mL, intra-assay
coefficient of variation = 13.8%), TIMP-2 (sensitivity =
9.8 pg/mL, intra-assay coefficient of variation = 8.4%),
OPG (sensitivity = 0.4 pg/mL, intra-assay coefficient
of variation = 8.9%), VEGF (sensitivity = 9.8 pg/mL,
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intra-assay coefficient of variation = 4.8%), MMP-3
(sensitivity = 19.6 pg/mL, intra-assay coefficient of variation = 8.9%), and IL-1b (sensitivity = 0.4 pg/mL, intraassay coefficient of variation = 8.2%).
Statistical Analyses

Data were analyzed using descriptive and inferential statistics with SPSS for Windows Version 18.0 (SPSS Inc.,
Chicago, IL) and GraphPad Prism (GraphPad Software,
Inc., La Jolla, CA) statistical programs. Data were evaluated for normal distributions by evaluating for skewness
and kurtosis. Because synovial fluid biomarker concentrations were not normally distributed, Mann Whitney
U tests were used to determine if significant differences
existed between the median values of two groups. A
two-way analysis of variance was used to determine if
differences in anti-inflammatory medication use affected
biomarker results. The alpha level (p ≤ 0.05) was
adjusted with Bonferroni corrections for the 8 biomarker comparisons (p ≤ 0.006).

Results

Table 1. The knees with effusion group consisted of 6
females and 5 males (mean age of 66.1 ± 9.4 years and
mean body mass index of 33.61 ± 6.40 kg/m2; nine with
Kellgren-Lawrence scores of 3 and two with KellgrenLawrence scores of 4). The knees without effusion
group consisted of 7 females and 4 males (mean age of
62.9 ± 5.3 years and mean body mass index of 34.26 ±
7.68 kg/m 2 ; nine with Kellgren-Lawrence scores of 3
and two with Kellgren-Lawrence scores of 4). Age and
body mass index were not significantly different between
the two groups. Three participants in the knees without
effusion group self-reported no history of knee swelling.
The remaining eight participants in the knees without
effusion group were currently having knee discomfort
and were not currently effused however, each reported a
history of knee swelling. The knees with effusion group
had 10 of 11 participants and the knees without effusion
group had 8 of 11 participants taking an anti-inflammatory medicine for management of their OA symptoms
(Table 1).

Participant characteristics

Biochemical distinction of knees with and without
effusion

Osteoarthritis (OA) was confirmed in each group radiographically; Kellgren-Lawrence scores are reported in

Median and confidence intervals for synovial fluid concentrations are presented in Table 2. The knees with

Table 1 Patient characteristics and medication use
Participant

Gender

KL Grade

Age

BMI

NSAID

Medication

1

Male

3

62

49.61

No

None

2

Female

4

67

34.64

No

Acetaminophen, calcium

Effusion group

3

Female

3

59

40.02

Yes

Ibuprofen

4

Female

3

55

30.73

Yes

Naproxen

5

Female

3

64

34.92

Yes

Ibuprofen

6
7

Female
Male

3
3

56
74

28.79
28.95

Yes
Yes

Ibuprofen
Ibuprofen, Acetaminophen

8

Male

3

85

28.25

Yes

Naproxen

9

Female

3

77

30.47

Yes

Ibuprofen

10

Male

4

68

29.33

Yes

Ibuprofen

11

Male

3

60

34.02

Yes

Naproxen, Glucosamine

12
13

Female
Male

3
3

65
69

36.07
35.05

No
No

Acetaminophen
Acetaminophen, Calcium

14

Male

4

66

41.23

No

Acetaminophen

15

Female

3

56

31.06

No

Acetaminophen

No effusion group

16

Female

3

70

31.65

Yes

Naproxen

17

Female

3

69

23.61

Yes

Chondroitin, Ibuprofen
Ibuprofen

18

Male

3

64

33.54

Yes

19

Male

3

59

29.11

Yes

Ibuprofen

20
21

Female
Female

3
4

59
57

39.14
50.95

Yes
Yes

Naproxen
Ibuprofen

22

Female

3

58

25.46

Yes

Acetaminophen, Ibuprofen

Note: KL = Kellgren Lawrence, BMI = Body Mass Index, NSAID = Nonsteroidal Anti-inflammatory Drug
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Table 2 Synovial fluid biomarker concentrations (pg/μg of total protein) of osteoarthritic knees with and without
effusion
Non-Effused (n = 11)

Effused (n = 11)

Median (95% CI)

Median (95% CI)

p value

r

IL-1b

0.000009
(0.000003 - 0.000023)

0.000012
(0.000006 - 0.000020)

0.714

-0.078

IL-10

0.000017
(0.000007 - 0.000039)

0.000054
(0.000037 - 0.000184)

0.003*

-0.625

IL-13

0.000057
(0.000038 - 0.000173)

0.000047
(0.000034 - 0.000087)

0.670

-0.091

TIMP-1

0.519388
(0.000000 - 13.457844)

52.008696
(38.851239 - 80.618044)

< 0.001*

-0.791

TIMP-2

0.340405
(0.000000 - 2.521999)

4.471101
(3.758427 - 5.662756)

0.002*

-0.665

MMP-3

0.130385
(0.000000 - 6.931912)

81.236149
(0.000000 - 334.057639)

< 0.001*

-0.819

OPG

0.000148
(0.000045 - 0.000281)

0.000104
(0.000116 - 0.000447)

0.224

-0.259

VEGF

0.001912
(0.000000 - 0.020470)

0.019389
(0.011830 - 0.033989)

0.013

-0.515

Biomarker

Note: CI = confidence interval, r = effect size, IL = interleukin, TIMP = tissue inhibitor of metalloproteinase, MMP = matrix metalloproteinase, OPG =
osteoprotegerin, and VEGF = vascular endothelial growth factor. * p ≤ 0.006 was considered significant.

effusion group had significantly higher IL-10 (217%),
TIMP-1 (9913%), and TIMP-2 (1213%) median concentrations (protective biomarkers) than the knees without
effusion group. The knees with effusion group also had
significantly higher median MMP-3 concentrations
(62204%; catabolic biomarker) than the knees without
effusion group. No other synovial fluid biomarker concentrations were statistically different. No significant
interaction (p = 0.322) was found between anti-inflammatory medication use and biomarker results when a
two-way analysis of variance was conducted.

Discussion
OA knees with effusion were biochemically distinct from
OA knees without effusion, providing support for the
hypothesis that effusion status may define an OA phenotype [11]. OA knees with effusion had elevated levels of
protective biomarkers (IL-10, TIMP-1, TIMP-2) and the
catabolic-associated biomarker MMP-3 compared to
knees without effusion. The current study is the first to
compare the biochemical profiles between OA knees with
and without effusion.
Three of the elevated biomarkers (TIMP-1, TIMP-2,
and MMP-3) in the OA knees with effusion group are
directly involved in the regulation of articular cartilage
extracellular matrix turnover [16,17]. MMP-3 is elevated
in nearly all diarthrodial joint OA tissues [18]. MMP-3
promotes proteoglycan breakdown and is expressed in a
stage-dependent manner: elevated higher in early-stage
OA than in late-stage OA [18]. TIMP-1 and TIMP-2,
inhibitors of MMPs, have also been reported to be elevated in knee OA [16]. The increase in protective biomarkers may represent a failing attempt to restore

homeostasis as the joint degenerates [19]. The current
study controlled for stage-dependent biochemical
changes by analyzing late-stage OA only (Kellgren-Lawrence score ≥ 3). The findings of the current study suggest
that the OA knees with effusion had greater extracellular
matrix turnover than the knees without effusion group,
at least at the time of synovial fluid collection. The
detected changes are indicative of active cellular processes at the time of fluid collection since eight of the eleven participants in the knees without effusion group had
prior history of knee effusion and biomarkers have short
life spans. However, it remains unclear if the increased
extracellular matrix turnover caused the effusion or if the
presence of effusion lead to increased extracellular matrix
turnover. Future studies should focus longitudinally on
effusion status, biochemical changes, and the progression
of changes in function and structure to determine
causality.
Anabolic and protective activity increases when there is
structural damage to the articular cartilage (e.g., macrotrauma, microtrauma) in an attempt to repair damaged
articular cartilage [20]. Collagen synthesis increases significantly in late-stage OA but is insufficient to promote
recovery [21]. The elevated protective biomarkers (i.e., IL10, TIMP-1, TIMP-2), as well as the increase in MMP-3,
in the knees with effusion group may suggest that these
knees were in a more active degenerative state compared
to the knees without effusion group. In a limited sample of
knees (n = 20) with minimal baseline cartilage damage, the
presence of synovitis or effusion led to a trend for
increased odds of rapid cartilage loss [8,9]. The knees with
effusion group may represent a unique subset of OA but
more research is needed to further define the subset
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characteristics (e.g., rate of disease progression). Additionally, further studies on biomarkers specific to collagen
turnover may help to validate that knees with effusion
may be an OA subset that are in a more active cartilage
degenerative state than knees without effusion.
Joint effusion is associated not only with cartilage turnover but also with synovitis. The use of imaging along
with biomarkers could help to determine the level of effusion associated with synovitis. Synovitis is common in OA
and not just to the end stage of the disease process, as
some degree of synovitis is present in early OA as well
[22]. A total of 57% of knees with synovitis are associated
with elevated concentrations of the inflammatory biomarker serum C-reactive protein [23]. The presence of synovitis does not always result in an increase in inflammatory
mediators. The OA knee without effusion could also be
generating inflammatory mediators. Based on the current
study, it is likely that synovitis with elevated inflammation
does not vary between groups, although IL-10 was elevated in the knees with effusion group compared to the
knees without effusion group. It is unclear which biochemical mediators stimulate IL-10, as IL-10 is elevated in
OA joints and associated with chondroprotective as well
as anti-inflammatory roles. In the temporomandibular
joint, a biochemical comparison of joints with and without
effusion demonstrated significant differences in the concentrations of soluble cytokine receptors but IL-1 receptor
antagonist was not statistically different [24]. The implications to the knee are yet to be determined, as it is
unknown if differences exist between different synovial
joints.
In the current study, medication and supplement use
were controlled for by having patients self-report their
use and then analyzing if there were any significant biochemical differences due to that use. Despite the disparity
in anti-inflammatory use between the two groups, none
of the inflammatory markers were statistically different
between groups. Accordingly, anti-inflammatory medication use had no overall effect on biomarker concentrations. Patients may need to consume anti-inflammatory
medication regularly for the medications to influence
biomarker concentrations. It is plausible that anti-inflammatory medication use did not affect biomarker concentrations because they were not consumed consistently,
but the study questionnaires were not designed to confirm consistent medication use. Future research should
be conducted on patients using a broad range of inflammatory mediators and more detailed medication use data
to determine the extent that medication use effects biochemical differences in knees with and without effusion.
The heterogeneity of OA is hindering progress in
developing new interventions and determining the effectiveness of existing interventions for OA. The concept
of phenotyping subsets of OA patients has begun to
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gain momentum [11,25,26], but which phenotypes are
clinically relevant remains unclear. More research is
needed to explore the biochemical differences between
an interaction of effusion status and symptoms (e.g.,
moderate-high symptoms with effusion, low symptoms
with effusion, low symptoms with non-effusion). This
may permit regression modeling to determine the association between clinical variables (e.g., quantification of
effusion, symptoms, and biochemical mediators) and the
development of individualized scores (continuous gradient model), taking one step forward in stratifying subsets/phenotypes [11].
OA stratifications may be dependent on stable variables
(e.g., mechanism of onset, genetic risk factors, involved
joints), transient variables (e.g., effusion), or their interaction. Effusion status is commonly conceptualized as a transient stratification; however, there may be a stable
stratification based on the history of knee effusion (e.g., no
history of knee effusion, history of knee effusion). In the
current study, three participants within the knees without
effusion group had no self-reported history of effusion.
These participants trended to having lower biomarker
concentrations than the other eight participants within the
knees without effusion group who self-reported a history
of effusion. The three participants with no self-reported
history of effusion were also three of the five knees with
the lowest concentrations of TIMP-1, TIMP-2, MMP-3,
and VEGF. Based on these findings, further research
should be conducted to determine if history of effusion
could possibly be used to determine stable stratifications
or phenotypes of OA. This may have implications when
assessing the effectiveness of interventions through clinical
trials. Each biochemical subset (stable or transient) may
respond differently to interventions. Future research
should focus on the effects of interventions on the biochemical level in an effort to improve the overall clinical
care of OA.
This study was limited by the cross-sectional design and
the relatively small sample size. Future studies would be
strengthened by increasing the sample size, as well as
longitudinally following the patients. Furthermore, the
lack of imaging modalities (e.g., magnetic resonance imaging, ultrasound) to objectively measure effusion and
synovitis levels limits the generalizability of the results.
Even with these limitations this study detected biochemical differences between knees with and without effusion
that warrants further research.

Conclusions
The biochemical differences that existed between knees
with and without effusion provide preliminary data based
on a relatively small sample size to support that OA subsets may exist, characterized by distinct biochemical
characteristics and clinical findings (e.g., effusion). These
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current data suggest that this area of research warrants
more attention in the future. Larger cohort studies
should be conducted to verify this finding. Presumably,
the biochemical distinction suggests that OA knees with
effusion may need to be managed differently than OA
knees without effusion.
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OA: osteoarthritis; MMP: matrix metalloproteinase;
TIMP: tissue inhibitor of MMPs; IL: interleukin; OPG:
osteoprotegerin; VEGF: vascular endothelial growth
factor.
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